Pharmaceutical Benefits Scheme change of Crohns disease
A change in the Pharmaceutical Benefits Scheme (PBS) from October 1, 2007, subsidized access to adults and children of Remicade (infliximab) to treat Crohns disease. Crohns disease is an inflammatory disease of the gastrointestinal tract. You can have a profound impact on working life, family and society. Those who have experience with chronic active Crohns disease abdominal pain, diarrhea and blood in the stool. Symptoms include fever, loss of appetite, fatigue and joint pain.About 2,000 more people will start Remicade for the treatment of Crohns disease in the first full year of trading. The extension to the list of Remicade is expected to add $ 53.9 million to PBS and Repatriation Pharmaceutical Benefits Scheme expenditure between 2007-08 and 2010-11. health.gov.